P/B
0,8
Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
$419.8M
Market Cap • 11/6/2026
2013
(13 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,8
EPS
—
Market Cap
Market Cap
419,8M
EV
-131,2M
EV/Revenue
-0,5
EV/EBITDA
4,3
EV/EBIT
3,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
17,4%
Total Yield
17,4%
Payout
0%
Retained Earnings
-1,6B
Profitability
Gross Margin
96,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
80,2%
Capex/Revenue
0,5%
Capex/D&A
55,6%
Capex/OCF
-0,9%
SBC/OCF
—
% PPE
1,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
65%
CAGR Op. Income 5Y
-28,9%
CAGR Net Income 5Y
-44,5%
CAGR EPS 5Y
-42,4%
Leverage
N.D./EBITDA
17,9
Debt/Equity
0%
Current Ratio
8,4
Quick Ratio
8,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!